NO20084182L - GSK-3 inhibitorer for behandling av osteoporose - Google Patents
GSK-3 inhibitorer for behandling av osteoporoseInfo
- Publication number
- NO20084182L NO20084182L NO20084182A NO20084182A NO20084182L NO 20084182 L NO20084182 L NO 20084182L NO 20084182 A NO20084182 A NO 20084182A NO 20084182 A NO20084182 A NO 20084182A NO 20084182 L NO20084182 L NO 20084182L
- Authority
- NO
- Norway
- Prior art keywords
- osteoporosis
- treatment
- bone
- gsk
- inhibitors
- Prior art date
Links
- 208000001132 Osteoporosis Diseases 0.000 title abstract 2
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 title 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- -1 4-methyl-1,4-diazepan-1-yl Chemical group 0.000 abstract 2
- 210000000988 bone and bone Anatomy 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- 230000011164 ossification Effects 0.000 abstract 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78025206P | 2006-03-08 | 2006-03-08 | |
| PCT/SE2007/000216 WO2007102770A1 (fr) | 2006-03-08 | 2007-03-06 | Inhibiteurs de gsk-3 destinés au traitement de l'ostéoporose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20084182L true NO20084182L (no) | 2008-12-05 |
Family
ID=38475142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20084182A NO20084182L (no) | 2006-03-08 | 2008-10-06 | GSK-3 inhibitorer for behandling av osteoporose |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7576093B2 (fr) |
| EP (1) | EP1993550A4 (fr) |
| JP (1) | JP2009529041A (fr) |
| KR (1) | KR20080114717A (fr) |
| CN (1) | CN101394851A (fr) |
| AR (1) | AR059754A1 (fr) |
| AU (1) | AU2007222199A1 (fr) |
| BR (1) | BRPI0708619A2 (fr) |
| CA (1) | CA2644751A1 (fr) |
| IL (1) | IL193484A0 (fr) |
| MX (1) | MX2008011417A (fr) |
| NO (1) | NO20084182L (fr) |
| TW (1) | TW200800203A (fr) |
| UY (1) | UY30192A1 (fr) |
| WO (1) | WO2007102770A1 (fr) |
| ZA (1) | ZA200807234B (fr) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100137330A1 (en) * | 2007-03-08 | 2010-06-03 | Ratan Bhat | Use |
| WO2010054398A1 (fr) | 2008-11-10 | 2010-05-14 | Vertex Pharmaceuticals Incorporated | Composés utiles comme inhibiteurs de l’atr kinase |
| AU2009327357C1 (en) | 2008-12-19 | 2017-02-02 | Vertex Pharmaceuticals Incorporated | Pyrazine derivatives useful as inhibitors of ATR kinase |
| WO2011089416A1 (fr) * | 2010-01-19 | 2011-07-28 | Astrazeneca Ab | Dérivés de pyrazine |
| WO2011143399A1 (fr) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Composés utiles en tant qu'inhibiteurs de l'atr kinase |
| WO2011143423A2 (fr) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Composés utilisables en tant qu'inhibiteurs de la kinase atr |
| MX2012013081A (es) | 2010-05-12 | 2013-05-09 | Vertex Pharma | Compuestos utiles como inhibidores de cinasa atr. |
| JP2013526540A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| WO2011143422A1 (fr) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Dérivés de 2-aminopyridine utiles en tant qu'inhibiteurs de la kinase atr |
| US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US8623869B2 (en) | 2010-06-23 | 2014-01-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| MX2013011450A (es) | 2011-04-05 | 2014-02-03 | Vertex Pharma | Compuestos de aminopirazina utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr). |
| PL2714677T3 (pl) * | 2011-05-23 | 2019-02-28 | Merck Patent Gmbh | Pochodne pirydynowe i pirazynowe |
| JP2014517079A (ja) | 2011-06-22 | 2014-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| WO2012178123A1 (fr) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Composés utiles comme inhibiteurs de la kinase atr |
| US9096602B2 (en) | 2011-06-22 | 2015-08-04 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors |
| EP2751088B1 (fr) | 2011-09-30 | 2016-04-13 | Vertex Pharmaceuticals Incorporated | Composés utiles en tant qu'inhibiteurs de kinase atr |
| RS59337B1 (sr) | 2011-09-30 | 2019-10-31 | Vertex Pharma | Postupak za izradu jedinjenja, korisnih kao inhibitori atr kinaze |
| EP2751099B1 (fr) | 2011-09-30 | 2017-06-14 | Vertex Pharmaceuticals Incorporated | Composés utiles comme inhibiteurs de kinase atr |
| SG11201401095YA (en) | 2011-09-30 | 2014-04-28 | Vertex Pharma | Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors |
| WO2013049720A1 (fr) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Composés utiles en tant qu'inhibiteurs de kinase atr |
| US8846917B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| EP2776419B1 (fr) | 2011-11-09 | 2016-05-11 | Vertex Pharmaceuticals Incorporated | Composés pyraziniques utiles en tant qu'inhibiteurs de l'atr kinase |
| US8841450B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| EP2776429A1 (fr) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Composés utiles comme inhibiteurs de kinase atr |
| WO2013071090A1 (fr) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Composés utiles en tant qu'inhibiteurs de la kinase atr |
| ES2654670T3 (es) | 2012-04-05 | 2018-02-14 | Vertex Pharmaceuticals Incorporated | Compuestos útiles como inhibidores de la cinasa ATR y terapias de combinación de los mismos |
| WO2014055756A1 (fr) | 2012-10-04 | 2014-04-10 | Vertex Pharmaceuticals Incorporated | Procédé pour la mesure d'augmentations de lésions d'adn à médiation par l'inhibition d'atr |
| EP2909202A1 (fr) | 2012-10-16 | 2015-08-26 | Vertex Pharmaceuticals Incorporated | Composés utiles en tant qu'inhibiteurs de la kinase atr |
| PT4190786T (pt) | 2012-12-07 | 2025-05-29 | Vertex Pharma | Compostos úteis como inibidores da quinase atr |
| CA3184040A1 (fr) | 2013-03-14 | 2014-10-02 | The Brigham And Women's Hospital, Inc. | Compositions et methodes d'expansion de cellule souche epitheliale comprenant un agoniste de wnt et un inhibiteur d'histone desacetylase |
| EP2970286A1 (fr) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Dérivés de pyrazolopyrimidine fusionnés utiles en tant qu'inhibiteurs de la kinase atr |
| CA2932757C (fr) | 2013-12-06 | 2023-10-31 | Vertex Pharmaceuticals Incorporated | Compose 2-amino -6-fluoro-n- [5-fluoro-pyridin -3-yl] pyrazolo [1,5-a] pyrimidine-3-carboxamide utile comme inhibiteur de la kinase atr, sa preparation, differentes formes solides et derives radiomarques de celui-ci |
| CN103804312B (zh) * | 2014-02-17 | 2016-04-20 | 四川百利药业有限责任公司 | 一类氮杂环化合物及其制备方法和用途 |
| KR102575125B1 (ko) | 2014-06-05 | 2023-09-07 | 버텍스 파마슈티칼스 인코포레이티드 | Atr 키나제의 저해제로서 유용한 2-아미노-6-플루오로-n-[5-플루오로-피리딘-3-일]-피라졸로[1,5-a]피리미딘-3-카복스아미드 화합물의 방사성표지된 유도체, 상기 화합물의 제조 및 이의 다양한 고체 형태 |
| RU2736219C2 (ru) | 2014-06-17 | 2020-11-12 | Вертекс Фармасьютикалз Инкорпорейтед | Способ лечения рака с использованием комбинации ингибиторов снк1 и atr |
| WO2016037016A1 (fr) | 2014-09-03 | 2016-03-10 | The Brigham And Women's Hospital, Inc. | Compositions, systèmes et procédés pour la production de cellules ciliées de l'oreille interne pour le traitement de la perte auditive |
| AU2016331955B2 (en) | 2015-09-30 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| AU2017205194A1 (en) | 2016-01-08 | 2018-07-19 | Massachusetts Institute Of Technology | Production of differentiated enteroendocrine cells and insulin producing cells |
| US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| CN110392686A (zh) | 2016-12-30 | 2019-10-29 | 频率治疗公司 | 1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法 |
| US11162071B2 (en) | 2018-08-17 | 2021-11-02 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by upregulating JAG-1 |
| WO2020037326A1 (fr) | 2018-08-17 | 2020-02-20 | Frequency Therapeutics, Inc. | Compositions et méthodes pour produire des cellules ciliées par la régulation à la baisse de foxo |
| JP2022520671A (ja) | 2019-02-08 | 2022-03-31 | フリークエンシー・セラピューティクス・インコーポレイテッド | 耳障害を治療するためのバルプロ酸化合物及びｗｎｔ作動薬 |
| AU2024294424A1 (en) * | 2023-07-14 | 2025-11-20 | Jazz Pharmaceuticals Therapeutics, Inc. | Methods of use of a liposomal composition comprising an atr inhibitor |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20013540A3 (cs) | 2000-02-05 | 2002-03-13 | Vertex Pharmaceuticals Incorporated | Deriváty pyrazolu jako inhibitory ERK a farmaceutický prostředek, který je obsahuje |
| SE0102438D0 (sv) * | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| SE0102439D0 (sv) * | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| EP1465610B1 (fr) * | 2002-01-10 | 2008-12-31 | F. Hoffmann-La Roche Ag | Utilisation d'un inhibiteur de gsk-3 beta dans la fabrication d'un medicament pour accroitre la formation osseuse |
| KR100974770B1 (ko) | 2002-03-05 | 2010-08-06 | 일라이 릴리 앤드 캄파니 | 키나제 억제제로서의 퓨린 유도체 |
| SE0203752D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| MXPA05013115A (es) | 2003-06-06 | 2006-05-25 | Wyeth Corp | Metodos y materiales para identificar agentes que modulan la remodelacion de hueso y agentes identificados por los mismos. |
| KR20060056377A (ko) | 2003-08-13 | 2006-05-24 | 카이론 코포레이션 | Ｇｓｋ-3 억제제 및 그것의 사용 |
| US20050064044A1 (en) * | 2003-09-19 | 2005-03-24 | Georges Rawadi | GSK-3beta inhibitors in the treatment of bone-related diseases |
-
2007
- 2007-03-02 TW TW096107083A patent/TW200800203A/zh unknown
- 2007-03-06 AR ARP070100917A patent/AR059754A1/es not_active Application Discontinuation
- 2007-03-06 JP JP2008558230A patent/JP2009529041A/ja active Pending
- 2007-03-06 BR BRPI0708619-9A patent/BRPI0708619A2/pt not_active IP Right Cessation
- 2007-03-06 AU AU2007222199A patent/AU2007222199A1/en not_active Abandoned
- 2007-03-06 WO PCT/SE2007/000216 patent/WO2007102770A1/fr not_active Ceased
- 2007-03-06 MX MX2008011417A patent/MX2008011417A/es not_active Application Discontinuation
- 2007-03-06 CA CA002644751A patent/CA2644751A1/fr not_active Abandoned
- 2007-03-06 KR KR1020087021787A patent/KR20080114717A/ko not_active Withdrawn
- 2007-03-06 EP EP07716035A patent/EP1993550A4/fr not_active Withdrawn
- 2007-03-06 CN CNA2007800079632A patent/CN101394851A/zh active Pending
- 2007-03-07 UY UY30192A patent/UY30192A1/es not_active Application Discontinuation
- 2007-03-08 US US11/683,458 patent/US7576093B2/en not_active Expired - Fee Related
-
2008
- 2008-08-14 IL IL193484A patent/IL193484A0/en unknown
- 2008-08-21 ZA ZA200807234A patent/ZA200807234B/xx unknown
- 2008-10-06 NO NO20084182A patent/NO20084182L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US7576093B2 (en) | 2009-08-18 |
| US20070213322A1 (en) | 2007-09-13 |
| WO2007102770A8 (fr) | 2008-01-31 |
| IL193484A0 (en) | 2009-08-03 |
| CN101394851A (zh) | 2009-03-25 |
| EP1993550A4 (fr) | 2010-04-21 |
| WO2007102770A1 (fr) | 2007-09-13 |
| TW200800203A (en) | 2008-01-01 |
| MX2008011417A (es) | 2008-09-22 |
| AR059754A1 (es) | 2008-04-30 |
| BRPI0708619A2 (pt) | 2011-06-07 |
| ZA200807234B (en) | 2009-09-30 |
| CA2644751A1 (fr) | 2007-09-13 |
| KR20080114717A (ko) | 2008-12-31 |
| UY30192A1 (es) | 2007-10-31 |
| AU2007222199A1 (en) | 2007-09-13 |
| JP2009529041A (ja) | 2009-08-13 |
| EP1993550A1 (fr) | 2008-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20084182L (no) | GSK-3 inhibitorer for behandling av osteoporose | |
| MY147780A (en) | Carboxamide compounds and their use as calpain inhibitors | |
| NO2023022I1 (no) | cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate | |
| IL165262A (en) | Kinase inhibitors and pharmaceutical compositions containing them | |
| IL165264A (en) | Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases | |
| DE60315492D1 (de) | Medizinisch verwendbare arylethanolamin verbindungen | |
| ATE307810T1 (de) | Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren | |
| SG128491A1 (en) | Heterocyclic sulfonamide inhibitors of beta amyloid production | |
| PT1940839E (pt) | Inibidores de piridopirimidinona pi3k alfa | |
| WO2006002099A3 (fr) | Inhibiteurs du facteurs xa | |
| CY1107974T1 (el) | Παραγωγα κινολινης και κιναζολινης εχοντα συναφεια προς τους υποδοχεις τυπου 5ht1 | |
| DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
| JP2009529041A5 (fr) | ||
| NO20052883L (no) | Nye medikamenter for behandling av kronisk obstruktiv luftveissykdom. | |
| TNSN03110A1 (fr) | Azaindoles. | |
| SE0104332D0 (sv) | Therapeutic agents | |
| ATE402141T1 (de) | Phenäthanolaminderivate zur behandlung von krankheiten der atemwege | |
| DE502004005033D1 (de) | Substituierte 2-aminotetraline zur behandlung von depressionen | |
| MX2011011764A (es) | Compuestos de carboxamida y su uso como inhibidores de calpaina. | |
| PL376324A1 (en) | Piperazinyl and diazapanyl benzamides and benzthioamides | |
| NO20051263L (no) | Ny anvendelse av benzotiazolderivater | |
| SV2003000633A (es) | Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7 | |
| UA99485C2 (ru) | Хиназолиндионовые производные, их получение и их применение в терапии | |
| EA200501703A1 (ru) | Применение производных азетидинкарбоксамида в терапии | |
| DE602004015277D1 (de) | Substituierte-1-phthalazinamine als vr-1-antagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |